Literature DB >> 10209655

Receptor-mediated mechanisms of lipoprotein remnant catabolism.

D A Chappell1, J D Medh.   

Abstract

Chylomicron and VLDL are triglyceride-rich lipoprotein particles assembled by the intestine and liver respectively. These particles are not metabolized by the liver in their native form. However, upon entry into the plasma, their triglyceride component is rapidly hydrolyzed by lipoprotein lipase and they are converted to cholesterol-rich remnant particles. The remnant particles are recognized by the liver and rapidly cleared from the plasma. This process is believed to occur in two steps. (i) An initial sequestration of remnant particles on hepatic cell surface proteoglycans, and (ii) receptor-mediated endocytosis of remnants by hepatic parenchymal cells. The initial binding to proteoglycans may be facilitated by lipoprotein lipase and hepatic lipase which possess both lipid- and heparin-binding domains. The subsequent endocytic process may be mediated by LDL receptors and/or LRP. Both receptors have a high affinity for apoE, a major apolipoprotein component of remnant particles. The lipases may also serve as ligands for these receptors. An impairment of any component of this complex process may result in an accumulation of remnant particles in the plasma leading to atherosclerosis and coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10209655     DOI: 10.1016/s0163-7827(98)00017-4

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  18 in total

1.  After chylomicron remnants, what is left?

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-06-10       Impact factor: 4.599

2.  Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.

Authors:  Gulam Hussain Syed; Huihui Tang; Mohsin Khan; Tarek Hassanein; Jingwen Liu; Aleem Siddiqui
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

3.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

4.  Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.

Authors:  J D Medh; G L Fry; S L Bowen; S Ruben; H Wong; D A Chappell
Journal:  J Lipid Res       Date:  2000-11       Impact factor: 5.922

Review 5.  Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.

Authors:  Koen Vercauteren; Ahmed Atef Mesalam; Geert Leroux-Roels; Philip Meuleman
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice.

Authors:  K Wilson; G L Fry; D A Chappell; C D Sigmund; J D Medh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-11       Impact factor: 8.311

7.  Lycopene stabilizes lipoprotein levels during D-galactosamine/lipopolysaccharide induced hepatitis in experimental rats.

Authors:  Sheik Abdulazeez Sheriff; Thiruvengadam Devaki
Journal:  Asian Pac J Trop Biomed       Date:  2012-12

Review 8.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

9.  Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor.

Authors:  David M Owen; Hua Huang; Jin Ye; Michael Gale
Journal:  Virology       Date:  2009-09-13       Impact factor: 3.616

10.  Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters.

Authors:  Tohru Ugawa; Hirotoshi Kakuta; Hiroshi Moritani; Osamu Inagaki
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.